First Line, %		Second Line, %		Third Line, %		Fourth Line, %		Median Duration, Months (Q1-Q3)
	MarketScan	PharMetrics	MarketScan	PharMetrics	MarketScan	PharMetrics	MarketScan	PharMetrics	MarketScan	PharMetrics
Radium-223	2.1	2.7	1.6	2.3	2.2	2.5	1.6	1.9	3.7 (2.0-5.6)	4.0 (1.9-5.9)
Abiraterone	49.6	42.5	37.2	37.7	33.7	33.5	26.3	26.4	7.9 (4.0-12.6)	7.8 (3.9-11.9)
Sipuleucel-T	14.7	18.6	3.0	3.0	0.7	1.2	0.7	0.4	1.4 (1.4-1.6)	1.4 (1.4-1.6)
Docetaxel	16.4	26.9	14.6	21.8	12.2	17.3	9.9	12.9	4.2 (2.6-5.6)	4.2 (2.8-5.6)
Cabazitaxel	0.8	1.1	1.3	1.6	1.5	1.8	2.1	3.2	2.1 (1.4-4.0)	2.1 (1.1-3.5)
Enzalutamide	18.4	10.3	20.5	14.9	21.2	13.6	19.8	13.8	5.0 (2.6-8.5)	4.6 (2.1-9.1)
Mitoxantrone	0.1	0.2	0.2	0.4	0.2	0.2	0.1	0.2	2.4 (2.1-6.4)	1.4 (0.7-2.1)
Antiandrogen	6.2	7.8	7.8	8.0	5.8	6.0	4.3	5.0	3.2 (1.9-7.4)	4.0 (2.1-7.5)
Other chemotherapy	23.4	25.5	56.6	62.1	28.3	31.5	41.7	38.1	9.2 (4.9-13.4)	7.0 (4.0-12.6)

Note: These results are not mutually exclusive. Not all patients moved through all 4 lines of therapy. Q1-Q3 = quarter 1 to quarter 3.